Polarean’s FDA cleared coil achieves important milestone, expanding clinical reach XENOVIEW® 3T coil passes Philips compatibility testing XENOVIEW® 3T Chest Coil is now confirmed for integration with Philips MRI systems starting in 2026 DURHAM, NC and LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces that its FDA-cleared XENOVIEW® 3T Chest Coil has successfully complet ...

Core Insights - Polarean Imaging has signed an exclusive distribution agreement with DK Healthcare for its Xenon MRI platform in South Korea, marking its second international distribution partnership and enhancing its commercial presence in the Asia-Pacific region [1][2]. Company Overview - Polarean Imaging is a leader in functional MRI technology for lung imaging, focusing on the direct visualization of lung function and addressing the unmet medical needs of over 500 million patients with chronic respiratory diseases globally [5]. - The company has developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is FDA-approved in the United States [5]. Partnership Details - The partnership with DK Healthcare aims to facilitate the regulatory clearances necessary for the commercial launch of the Xenon MRI platform in South Korea, a market known for its advanced medical imaging capabilities [2][4]. - DK Healthcare, a prominent provider of diagnostic radiology systems in Korea, has a strong reputation for delivering innovative imaging solutions and support [3][6]. Market Potential - South Korea's focus on early detection and precision medicine positions it as an ideal growth market for Polarean's technology, which enhances lung function assessment and aims to improve outcomes for patients with conditions such as lung cancer and COPD [4].

Core Insights - Polarean Imaging plc is gaining recognition for its innovative Xenon MRI platform, which is being highlighted at major respiratory medicine conferences, indicating its growing importance in clinical imaging and drug development [2][3][5] Group 1: Company Overview - Polarean Imaging is a commercial-stage medical imaging technology company focused on functional MRI of the lungs, aiming to improve lung health and address unmet medical needs for over 500 million patients with chronic respiratory diseases [10] - The company has developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is FDA-approved for evaluating lung ventilation in adults and pediatric patients aged 12 years and older [11][10] Group 2: Conference Participation - Polarean will be featured at the American Thoracic Society's 2025 Respiratory Innovation Summit and the ATS 2025 International Conference, showcasing its commitment to engaging with leaders in pulmonary medicine [1][5] - At the ATS 2025 International Conference, Xenon MRI will be presented in over 30 posters and presentations from more than 10 leading clinical sites, demonstrating its sustained momentum and expanding role in clinical care and trials [3][6] Group 3: Research and Development - The presentations at the conferences will cover a wide range of respiratory conditions, including asthma, COPD, COVID-19, and pulmonary arterial hypertension, highlighting the versatility of Xenon MRI [4][6] - The company emphasizes the importance of building partnerships and strengthening collaborations with clinicians, researchers, and patient advocates to advance the field of functional lung imaging [5][6]